AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01002872 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Initial dose of placebo will be 1 pill three times a day
Study NCT00972348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online access to a personal health record
Description: Patients in the intervention arm have full access to their online personal health record
Study NCT00972348 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No access to the PHR
Description: Patients will not be given access to their PHR but will complete online surveys.
Study NCT00643058 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LPS endotoxin
Description: Low challenge: saline (diluent), 5000EU, 10,000EU and 20,000EU LPS endotoxin as tolerated~High challenge: Saline (diluent), 40,000EU and 80,000EU as tolerated~Diluent Challenge: 3 X Sterile saline inhalation (2 ml)
Study NCT01357616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension
Study NCT01357616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide 1% ophthalmic suspension
Study NCT01357616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol 0.5% ophthalmic solution
Study NCT02961023 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise therapy
Description: 3-week residential phase and 12-week outpatient phase.~Residential phase~* Exercise will be supervised by a physiotherapist and prescribed based on cardiopulmonary exercise testing.~* A monitored daily program of exercise involving bicycle ergometry, walking, breathing exercises, dumbbell exercises 5 days per week.~* 1.5 to 2 hours of exercise will be performed daily, with rest intervals.~* At weekends, lower intensity, unsupervised exercise mirroring the outpatient phase~* Ongoing exercise prescription will be based on tolerability, progress and HR~Outpatient phase~* A training manual will be compiled based on the subjects exercise performance during the residential program and tailored specifically to their needs~* Participants will be provided with a cycle ergometer, weights and a HR monitor~* Weekly telephone contact will be made by the study doctor or physiotherapist, with adjustments made to training prescription as necessary
Study NCT00603902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice a day (BID)
Description: Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.
Study NCT00603902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching placebo tablet each morning and evening for a duration of 52 weeks.
Study NCT02701530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted smoking cessation
Description: Smoking cessation program developed in cooperation with and aimed at smokers with low education.
Study NCT03857217 — intervention group
Intervention type: DEVICE
Intervention: Extra-Corporeal Membrane Oxygenation
Description: ECMO is implanted in cardiac surgery patients.
Study NCT02171312 — intervention group
Intervention type: DEVICE
Intervention: iDETECT Assessment
Description: The iDETECT device is an open platform for an evaluation of cognitive, balance, and oculomotor performance after mild traumatic brain injury (mTBI). It is a rugged, portable, neurocognitive assessment tool designed specifically for use in field and triage settings for the rapid evaluation of functional neurologic impairment after potential concussive injury. The apparatus includes an enhanced heads-up display visor with integration motion detection technology, noise-reducing headphones optimized with pink noise, and a handheld display for test battery administration, subject response inputs, and user data output. iDETECT will be used to assess multimodal neurologic function in participants.
Study NCT02171312 — intervention group
Intervention type: BEHAVIORAL
Intervention: Routine Balance and Vestibular Testing
Description: A clinician will assess balance and vision by standard of care routine tests for neurologic function.
Study NCT02961023 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: 3-week residential phase and 12-week outpatient phase.~Residential phase~* Exercise will be supervised by a physiotherapist and prescribed based on cardiopulmonary exercise testing.~* A monitored daily program of exercise involving bicycle ergometry, walking, breathing exercises, dumbbell exercises 5 days per week.~* 1.5 to 2 hours of exercise will be performed daily, with rest intervals.~* At weekends, lower intensity, unsupervised exercise mirroring the outpatient phase~* Ongoing exercise prescription will be based on tolerability, progress and HR~Outpatient phase~* A training manual will be compiled based on the subjects exercise performance during the residential program and tailored specifically to their needs~* Participants will be provided with a cycle ergometer, weights and a HR monitor~* Weekly telephone contact will be made by the study doctor or physiotherapist, with adjustments made to training prescription as necessary
Study NCT00640627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg oral capsule once daily for 6 weeks
Study NCT00640627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched oral placebo for 6 weeks
Study NCT02332720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Part A: one grazoprevir 100 mg tablet taken q.d. by mouth.
Study NCT02619864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Study NCT03125538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery
Description: Together with physical rehabilitation performed with physiotherapists, participants from the experimental group will mentally rehearse 3 different locomotor exercises that they already physically performed beforehand.~Exercise 1: 10m Walk~Exercise 2: Timed Up and Go test (rise up from a chair, walk 3 meters, turn around, come back to the chair, turn around and sit down)~Exercise 3: Stairs climbing test (climb up 4 stairs, turn around, climb down the for stairs)~Two min of MIP will be scheduled 5 times/day, during rest periods, so that patients complete 10min of MIP per day.
Study NCT03125538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Task
Description: Together with physical rehabilitation performed with physiotherapists, participants from the control group will spend equivalent time focusing on a cognitive task without impact on motor rehabilitation ((word scramble game).~Two min of this cognitive task will be scheduled 5 times/day, during rest periods, so that patients complete 10min of control task per day.
Study NCT01985191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR405838
Description: Pharmaceutical form:capsule~Route of administration: oral
Study NCT01985191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT01231724 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Allstate Nasal Spray
Description: Allstate Nasal Spray, two sprays (total 100 microliters) in each nostril.
Study NCT01231724 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: 2 sprays in each nostril
Study NCT02022280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Study NCT02022280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vitamin pill
Study NCT01371110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine hydrochloride is a nonbarbiturate anesthetic. It is formulated as a slight acid (pH 3.5 to 5.5) sterile solution for intravenous or intramuscular injection in concentrations containing the equivalent of either 50 or 100mg ketamine base per milliliter.
Study NCT01371110 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Midazolam
Description: Midazolam is a short-acting benzodiazepine central nervous (CNS) depressant.
Study NCT02894944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Theragene®,Ad5-yCD/mutTKSR39rep-ADP
Description: Theragene®,Ad5-yCD/mutTKSR39rep-ADP is Adenovirus-mediated Double Suicide Gene Therapy
Study NCT00781040 — intervention group
Intervention type: OTHER
Intervention: Severe sepsis vs. non-severe sepsis
Description: To compare these two groups
Study NCT02332720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Part A: two or three uprifosbuvir 150 mg (300 or 450 mg total daily dose) tablets taken q.d. by mouth.
Study NCT04173780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine 0.01%
Description: 1 drop per day in both eyes for 1 year
Study NCT04173780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 drop per day in both eyes for 1 year
Study NCT04670952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Pressure Laparoscopic Cholecystectomy
Description: Low Pressure Laparoscopic Cholecystectomy (10mmHg) is set as the experimental group.
Study NCT02332720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Part A: one elbasvir 50 mg tablet taken q.d. by mouth.
Study NCT04670952 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Pressure Laparoscopic Cholecystectomy
Description: Standard Pressure Laparoscopic Cholecystectomy (14mmHg) is set as the control group.
Study NCT01113385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Galactose
Description: Oral galactose will be initiated at a dose of 0.2gm/kg/dose twice daily to a maximum of 15 gm BID for a period of 4 months. The prescribed dose of D-galactose powder will be dispensed to subjects in packets, mixed with 4 ounces of water, and consumed orally.
Study NCT03813901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Samalochana Counselling
Description: Counselling program was individual, based on advaita vedanta and traditional philosophical grounds to answer individual fears, concerns,conflicts and difficulties in order to cope and recover.
Study NCT03813901 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wait list control
Description: Wait list had no intervention offered during the study period. Afterwards, they were offered the counselling for the same duration.
Study NCT02547415 — intervention group
Intervention type: OTHER
Intervention: questionnaires and psychological testing
Description: Child/adolescent and parents interview and consultation with both a physician and a psychologist for a somatic and pain indicators assessment within an usual setting.~Then, parents and child or adolescent are interviewed separately using different psychological instruments with only a psychologist:~* Psychological (cognitive and projective evaluation) : Intellectual Quotient, mental flexibility, projective evaluation with Rorschach and Thematic Apperception Test, parents and children attachment questionnaires~* Psychopathological: anxiety and depression questionnaires, psychiatric disorders evaluation, quality of life, life events questionnaires, family functioning interview.
Study NCT03172923 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sliding hip screw
Description: fixation of the fracture with a sliding hip screw
Study NCT03172923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intramedullary nial
Description: fixation of the fracture with an intramedullary nail
Study NCT03146455 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT02332720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: Part A: six ruzasvir 10 mg (60 mg total daily dose) capsules taken q.d. by mouth.
Study NCT02332720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3682B
Description: Part B and Part C: two FDC tablets, each containing grazoprevir 50 mg + elbasvir 225 mg + ruzasvir 30 mg, taken q.d. by mouth.
Study NCT01786135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD19A
Description: SGN-CD19A (IV) once every 21 days (3 weeks) or 42 days (6 weeks)
Study NCT02332720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Part B and Part C: RBV 200 mg capsules taken b.i.d. by mouth at a total daily dose of 800 mg - 1400 mg based on participant body weight.
Study NCT03377543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 81mg aspirin pill daily at bedtime over a 25 day period
Study NCT03377543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 81mg non-active pill that looks like aspirin
Study NCT02336243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Description: Docosahexaenoic acid (DHA), 600 mg per day. Each woman will take three DHA capsules per day (200 mg each), as early in gestation as possible and until the end of pregnancy.
Study NCT02336243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Docosahexaenoic acid (DHA))
Description: Each women allocated to the placebo group, will receive three placebo capsules per day. The placebo capsules will have same size, aspect and flavor than the DHA capsules.
Study NCT04021810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) and patient education
Description: Mask connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airways. Plus patient education.
Study NCT04021810 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP) and patient education
Description: Mask connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airways. Plus patient education.
Study NCT04021810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device
Description: Adjustable oral prosthesis which retains the lower mandible in an anterior position, thus limiting sleep apneas
Study NCT04021810 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular Advancement Device
Description: Adjustable oral prosthesis which retains the lower mandible in an anterior position, thus limiting sleep apneas
Study NCT02984657 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical patients in 2012 with anesthesia and nursing staff less attuned to intraoperative RTP.
Description: RTP, reverse Trendelenburg positioning
Study NCT02984657 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical patients in 2015 with enhanced anesthesia and nursing staff awareness and use of intraoperative RTP.
Description: RTP, reverse Trendelenburg positioning
Study NCT02396654 — intervention group
Intervention type: OTHER
Intervention: 2D and 5D LB ultrasound comparison for fetal weight estimation
Description: 2D and 5DUS LB will be done for term pregnant women and fetal weight will be estimated by the hadlock formula. Accuracy of estimated fetal weight by both techniques will be compared to actual birth weight.
Study NCT00510094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Friend to Friend program
Description: Friend to Friend arm is a social information processing group treatment to help aggressive girls learn better social problem solving and decision making choices. Participants will learn how to identify signs of physiological arousal, evaluate others' intentions, react to a potential conflict situation, and generate and evaluate alternatives. Treatment sessions are twice per week (30 to 40 minutes per session) for ten weeks.
Study NCT00510094 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational attention control intervention
Description: Psychoeducational attention control group also meets two times per week for 10 weeks to control for nonspecific factors of treatment. Participants learn homework, study skills, and organizational skills.
Study NCT00677833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin plus Chloroquine
Description: Combination of Azithromycin plus Chloroquine Azithromycin (\~30 mg/kg) + chloroquine (\~10mg base /kg) combination tablet(s) on weight basis, once daily for 3 days (Days 0,1,2) or Artemether-lumefantrine tablet(s) based on weight and labeling for 3 days (Days 0, 1, 2)
Study NCT00677833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: Artemether-lumefantrine tablet(s) based on weight and labeling for 3 days (Days 0, 1, 2)
Study NCT02925910 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Shock absorbing wheelchair
Description: 2 randomised groups will try the softwheel wheelchair compare to regular one, but in different order.
Study NCT03432364 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ST-400 Investigational product
Description: Single dose of ST-400 following chemotherapy conditioning with busulfan
Study NCT03288610 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Preoperative copeptin level
Description: Measure of plasmatic copeptin from preoperative samples retained in a biorepository. Physicians are blinded to the result.
Study NCT03236298 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CADD-Solis Ambulatory Infusion System
Description: The CADD-Solis pump will administer programmed intermittent boluses of 0.0625% Bupivacaine plus fentanyl 2mcg/ml.
Study NCT01993225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal 12.5 mg/25 mg
Study NCT01993225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Capsules
Study NCT01993225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Study NCT01993225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AndroGel 1.62%
Study NCT01993225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Gel
Study NCT01993225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Study NCT04646655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: subcutaneous injections
Study NCT04646655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: subcutaneous injections
Study NCT04493216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 was available as a 25 mg and 100 mg tablets to be administered via oral route.
Study NCT04493216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC/3TC
Description: ABC/3TC was available as abacavir 600 mg/lamivudine 300 mg tablet to be administered via oral route.
Study NCT04493216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC/3TC
Description: ABC/3TC was available as abacavir 600 mg/lamivudine 300 mg tablet to be administered via oral route.
Study NCT04493216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TAF
Description: FTC/TAF was available as emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet to be administered via oral route.
Study NCT04493216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TAF
Description: FTC/TAF was available as emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet to be administered via oral route.
Study NCT04493216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir
Description: Dolutegravir was available as a 50 mg tablet to be administered via oral route.
Study NCT04493216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching GSK3640254 was administered in the form of tablets via oral route.
Study NCT00770107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiamine
Description: Supplementation of thiamine (vitamin b1) 300 mg per day, once daily, for a duration of 4 weeks
Study NCT00770107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily, for a duration of 4 weeks
Study NCT00900874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salbutamol
Description: two puffs (100 microgram each of salbutamol) by MDI and spacer
Study NCT00900874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Formoterol 2 puffs (6 µg /puff) by MDI and spacer
Study NCT02808936 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: three cycles of ischemia (5 min) / reperfusion (5 min) of available upper or lower limb with an automated machine using blood pressure cuff
Study NCT02808936 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: The patients had the same pneumatic cuff around the upper arm and similar maneuvers were performed, but pressure was not applied to the cuff.
Study NCT01224301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School based flu vaccine: Low intensity
Description: Interventions: Parents of children in Low Intensity Notification schools got less than 3 communications from schools describing influenza vaccine and the clinics, and consent forms sent home one.
Study NCT01224301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School based flu vaccine: High intensity
Description: Interventions: Parents in high intensity schools have 3 or more communications from schools about influenza illness, influenza vaccine, and school based clinics.
Study NCT02366910 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: Each subject randomized to wear either the test or control in either the left of right eye.